In silico screening for identification of novel drugs for overcoming taxane-resistant prostate cancer

被引：0
|
作者：
Hongo, Hiroshi [1 ]
Kosaka, Takeo [2 ]
Miyazaki, Yasumasa [2 ]
Tanaka, Nobuyuki [2 ]
Oya, Mototsugu [2 ]
机构：
[1] Nerima Gen Hosp, Dept Urol, Tokyo, Japan
[2] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan
来源：
CANCER SCIENCE | 2021年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PJ17-2-5
引用
收藏
页码：916 / 916
页数：1
相关论文
共 50 条
  • [41] Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer
    Bunnell, Craig
    Vahdat, Linda
    Schwartzberg, Lee
    Gralow, Julie
    Klimovsky, Judith
    Poulart, Valerie
    Peck, Ronald
    Thomas, Eva
    CLINICAL BREAST CANCER, 2008, 8 (03) : 234 - 241
  • [42] Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells
    Adediran, Samusi
    Wang, Linbo
    Khan, Mohammad Afnan
    Guang, Wei
    Fan, Xiaoxuan
    Dan, Hancai
    Qi, Jianfei
    Jay, Steven M.
    Carrier, France
    Hussain, Arif
    CANCERS, 2022, 14 (19)
  • [43] Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer
    Blagden, S.
    Olmos, D.
    Sharma, R.
    Barruiso, J.
    Medani, H.
    Versola, M.
    Murray, S.
    Smith, D. A.
    Dar, M. M.
    deBono, J. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 135 - 135
  • [44] A Novel Microtubule Inhibitor 4SC-207 with Anti-Proliferative Activity in Taxane-Resistant Cells
    Bausch, Elena
    Kohlhof, Hella
    Hamm, Svetlana
    Krauss, Rolf
    Baumgartner, Roland
    Sironi, Lucia
    PLOS ONE, 2013, 8 (11):
  • [45] Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer
    Bowerman, Charles J.
    Byrne, James D.
    Chu, Kevin S.
    Schorzman, Allison N.
    Keeler, Amanda W.
    Sherwood, Candice A.
    Perry, Jillian L.
    Luft, James C.
    Darr, David B.
    Deal, Allison M.
    Napier, Mary E.
    Zamboni, William C.
    Sharpless, Norman E.
    Perou, Charles M.
    DeSimone, Joseph M.
    NANO LETTERS, 2017, 17 (01) : 242 - 248
  • [46] Targeting Dynamin-related protein 1 for the management of taxane-resistant triple-negative breast cancer
    Terrero, David
    Tiwari, Amit
    Raman, Dayanidhi
    CANCER RESEARCH, 2023, 83 (05)
  • [47] Phase II study of irinotecan plus oral etoposide in patients with platinum and taxane-resistant ovarian cancer.
    Nishio, S
    Sugiyama, T
    Shoji, T
    Kitagawa, R
    Ushijima, K
    Kamura, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 479S - 479S
  • [48] Castration-resistant Prostate Cancer: Novel Therapeutics Pre-or Post-Taxane Administration
    Shiota, Masaki
    Yokomizo, Akira
    Fujimoto, Naohiro
    Kuruma, Hidetoshi
    Naito, Seiji
    CURRENT CANCER DRUG TARGETS, 2013, 13 (04) : 444 - 459
  • [49] Veru-111 as an orally available tubulin inhibitor suppressing both taxane-sensitive and taxane-resistant triple-negative breast cancer
    Li, Wei
    Deng, Shanshan
    Krutilina, Raya
    Miller, Duane
    Seagroves, Tiffany
    CANCER RESEARCH, 2021, 81 (04)
  • [50] Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer
    Vivas-Mejia, Pablo E.
    Rodriguez-Aguayo, Cristian
    Han, Hee-Dong
    Shahzad, Mian M. K.
    Valiyeva, Fatma
    Shibayama, Mineko
    Chavez-Reyes, Arturo
    Sood, Anil K.
    Lopez-Berestein, Gabriel
    CLINICAL CANCER RESEARCH, 2011, 17 (11) : 3716 - 3726
12345